Regulation of bace degradation

Abstract

The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid β.

1 . A method for diagnosing a disorder associated with altered β-secretase processing of substrates, comprising
 measuring the stability and/or amount of a GGA protein in a biological sample from a subject, wherein decreased protein stability and/or amount relative to that in a control biological sample is an indication that the subject has a disorder associated with altered β-secretase processing of substrates, wherein the disorder associated with altered β-secretase processing of substrates is selected from the group consisting of cancer, immunologic diseases, glycoconjugate metabolism disorders, body myositis and hereditary inclusion body myopathies, head trauma, hypoglycemia, and any neurodegenerative disorder with increased caspase activation. 
 
     
     
         2 . The method of  claim 1 , wherein the GGA protein is GGA1, GGA2 or GGA3. 
     
     
         3 . The method of  claim 2 , wherein the GGA protein is GGA3. 
     
     
         4 . The method of  claim 1 , wherein the subject is human. 
     
     
         5 . The method of  claim 1 , wherein the biological sample is selected from the group consisting of cells and tissues. 
     
     
         6 . The method of  claim 5 , wherein the cells are neuronal cells. 
     
     
         7 . The method of  claim 5 , wherein the tissue comprises neuronal cells. 
     
     
         8 . A method for determining onset, progression, or regression, of a disorder associated with altered β-secretase processing of substrates in a subject, comprising:
 measuring the stability and/or amount of a GGA protein in a first biological sample of a subject, 
 measuring the stability and/or amount of the GGA protein in a second biological sample of a subject obtained at a second time, and 
 comparing the measurement of stability and/or amount in the first sample to the measurement of stability and/or amount in the second sample as a determination of the onset, progression, or regression of the disorder associated with altered β-secretase processing of substrates, wherein the disorder associated with altered β-secretase processing of substrates is selected from the group consisting of cancer, immunologic diseases, glycoconjugate metabolism disorders, body myositis and hereditary inclusion body myopathies, head trauma, hypoglycemia, and any neurodegenerative disorder with increased caspase activation. 
 
     
     
         9 . The method of  claim 8 , wherein the GGA protein is GGA1, GGA2 or GGA3. 
     
     
         10 . The method of  claim 9 , wherein the GGA protein is GGA3. 
     
     
         11 . The method of  claim 8 , wherein the subject is human. 
     
     
         12 . The method of  claim 8 , wherein the biological sample is selected from the group consisting of cells and tissues. 
     
     
         13 . The method of  claim 12 , wherein the cells are neuronal cells. 
     
     
         14 . The method of  claim 12 , wherein the tissue comprises neuronal cells.